TriangleHEALTH PROFESSIONAL · SOURCE READING
Chemotherapy for advanced disease
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for Soft Tissue Sarcoma / Chemotherapy
Anthracyclines remain the first-line class of systemic therapy in managing most locally advanced and metastatic soft tissue sarcoma.[61]
Source links and citations
Other regimens, approved for use as second-line therapy and beyond, include:
Gemcitabine/docetaxel.[62]
Source links and citations
Ifosfamide.
Trabectedin (liposarcoma and leiomyosarcoma).[63]
Source links and citations
Eribulin (liposarcoma).[64]
Source links and citations
Pazopanib.[65]
Source links and citations
Dacarbazine.
Pegylated liposomal (encapsulated) doxorubicin.[66]
Source links and citations
Taxanes or taxane combinations are used for patients with angiosarcomas.
The clinical benefit of adding other drugs to the single-agent doxorubicin regimen is controversial.
In randomized studies, the combination of doxorubicin with ifosfamide has not demonstrated superiority over doxorubicin alone in terms of OS, but adding ifosfamide to doxorubicin may be considered in cases where reaching a better response to treatment, despite more toxicity, is the main treatment goal.[52,67]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice